VDN | Vaccine Pipeline
Sponsor & Developer Portfolio

BioNTech

Clinical development pipeline, platform architecture, and registered trial tracking for BioNTech vaccine candidates.

10
Candidates
8
Target Diseases
11
Linked Studies

Development Phase Distribution

Phase 3 Clinical Trial: 4 Phase 1 Clinical Trial: 3 Phase 2 Clinical Trial: 2 Discontinued / Inactive: 1

Platform Technologies

Biological (unspecified platform): 8 Protein / subunit: 1 mRNA: 1

Target Pathogens & Indications

COVID-19 Genital Herpes Simplex Type 2 HPV Metastatic Melanoma Mpox Non-Small Cell Lung Cancer Solid Tumor Tuberculosis

Vaccine Pipeline Candidates (10)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Discontinued / Inactive ctgov-neo-pv-01-biontech-us-inc

APX005M

Target: Metastatic Melanoma

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2020-05-05 (registry estimate)
View Full Clinical Profile →
Phase 1 Clinical Trial ctgov-bnt116-biontech-se

BNT116

Target: Non-Small Cell Lung Cancer

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2030-02 (registry estimate)
View Full Clinical Profile →
Phase 1 Clinical Trial ctgov-bnt163-biontech-se

BNT163

Target: Genital Herpes Simplex Type 2

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-10 (registry estimate)
View Full Clinical Profile →
Phase 1 Clinical Trial ctgov-cldn6-car-t-biontech-cell-gene-therapies-gmbh

CLDN6 CAR-T

Target: Solid Tumor

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-08 (registry estimate)
View Full Clinical Profile →
Phase 2 Clinical Trial ctgov-bnt164a1-biontech-se

BNT164a1

Target: Tuberculosis

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-03-12 (registry estimate)
View Full Clinical Profile →
Phase 2 Clinical Trial ctgov-bnt166a-biontech-se

BNT166a

Target: Mpox

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-06 (registry estimate)
View Full Clinical Profile →
Phase 3 Clinical Trial ctgov-bnt113-biontech-se

BNT113

Target: HPV

Platform: Protein / subunit

Key Milestone: Primary completion (most advanced trial): 2029-04 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-bnt162b2-2025-2026-formulation-biontech-se

BNT162b2 (2025/2026 formulation)

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-07-31 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-bnt162b2-vaccine-biontech-se

BNT162b2 Vaccine

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-07-31 (registry estimate)
View Full Clinical Profile → Disease Hub →
Phase 3 Clinical Trial ctgov-bivalent-bnt162b2-original-omicron-ba-4-ba-5-3-microgram-dose-bi

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-07-23 (registry estimate)
View Full Clinical Profile → Disease Hub →

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →